Abstract 836
Background
In this retrospective cohort study based in Taiwan, we reported the current epidemiology of patients with multiple myeloma and analyzed the effect of bortezomib-based therapy on clinical outcomes.
Methods
We identified 5726 patients with newly diagnosed multiple myeloma (MM) between 2007 and 2015 in Taiwan. Privileges data from the National Health Institute Research Database was used, as it is made readily available to the public in electronic format for research purposes.
Results
Among them, from January 2007 to October 2011, there were 1116 multiple myeloma patients (control group: bortezomib as non-first-line drug), and there were 4610 multiple myeloma patients from November 2011 to December 2015.The results showed that in the case group the proportion of hospital deaths in the future was 15.73% (702/4464), while the proportion of hospital deaths in the control group was 19.80% (221/1116). The patient with first-line with bone marrow transplantation, the first-line without bone marrow transplantation, the non-first-line with bone marrow transplantation, the probability of hospital death risk was 0.387 times higher than that of the non-first-line without bone marrow transplantation) (P < 0.001) ), 0.681 times (P < 0.001), 0.724 times (P = 0.035).
Conclusions
In conclusion, our study showed that the first-line effect of bortezomib-based therapy on clinical outcomes for Taiwanese patients with multiple myeloma was better than the non-first line. To provide the most representative data on Bortezomib treatment results of MM patients achievable in Taiwan, we could prospectively collect nationwide data including detailed information. This could not only provide stage-stratified survival and disease-specific survival rates but also help to identify better clinical effects.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5141 - Mutational profiling of tumor tissue and sequential plasma illustrates emergent clones during treatment in late stage small cell lung cancer (SCLC)
Presenter: Stephanie Yaung
Session: Poster Display session 1
Resources:
Abstract
5189 - Association between serum HGF levels and neutrophil counts in small cell lung cancer and their impact on survival
Presenter: Laura Moliner
Session: Poster Display session 1
Resources:
Abstract
3539 - Prognostic role of RLF/MYCL1 and circPVT1 in SCLC.
Presenter: Clelia Tiziana Storlazzi
Session: Poster Display session 1
Resources:
Abstract
3438 - High-biologically effective dose radiotherapy improve the survival of small cell lung cancer patients with brain metastases: a propensity-matching analysis
Presenter: Qingyang Zhuang
Session: Poster Display session 1
Resources:
Abstract
3232 - Phase 1 open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer
Presenter: Emiliano Calvo
Session: Poster Display session 1
Resources:
Abstract
3633 - Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer
Presenter: Carminia Maria Della Corte
Session: Poster Display session 1
Resources:
Abstract
3745 - Multi-level proteomics identifies FABP5 as a primary chemoresistance mediator in extensive-stage small cell lung cancer
Presenter: Yamei Chen
Session: Poster Display session 1
Resources:
Abstract
5049 - CLEPSIDRA trial: a pilot, biomarker-guided study to assess safety, tolerability, dose finding and efficacy of iadademstat in combination with platinum-etoposide in patients with relapsed, extensive-stage small cell lung cancer
Presenter: Alejandro Navarro Mendivil
Session: Poster Display session 1
Resources:
Abstract
5997 - Phased Avelumab combined with chemotherapy as first-line treatment for patients with advanced small-cell lung cancer (SCLC): The PAVE study, a Hellenic Cooperative Oncology Group Study
Presenter: Helena Linardou
Session: Poster Display session 1
Resources:
Abstract
4502 - Tobacco use in lung cáncer (LC) patients (p) in Spain
Presenter: Enric Carcereny Costa
Session: Poster Display session 1
Resources:
Abstract